$ACI

Transcript: Albertsons Companies Q2 2026 Earnings Conference Call - Albertsons Companies (NYSE:ACI)

Albertsons (NYSE:ACI) reported Q2 2026 identical sales down 0.8%, adjusted EBITDA $784M, and adjusted EPS $0.36. E-commerce sales grew 11%, while pharmacy sales remained strong. The company aims for $2B in cost savings over three years and is reviewing its business to enhance shareholder value. Albertsons generated $1.2B in operating cash flow and repurchased $400M in shares in the first half of 2026.

Original reporting
Published Oct 13, 2026, 1:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 1:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ACI
Bearish
high confidence
Mentioned
$ACI
Relevance
7/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$ACIBearishMed
01

Why it matters

The earnings miss may trigger short‑term sell pressure, but the announced cost‑reduction program could provide upside if execution improves.

02

Market read

The earnings release provides fresh data that could move ACI and influence peer grocery stocks.

03

What to watch

Strong e‑commerce growth (11%) and pharmacy resilience may offset the sales decline over the longer term.

Relevance 7/10Novelty 7/10Timing: after-hours release

Background

Albertsons Companies (ACI) reported Q2 2026 results, highlighting a slight drop in comparable sales and outlining a $2B cost‑saving plan over three years.

Company-level read

Ticker impact

$ACIBearishHigh confidence
Context

Q2 2026 earnings call disclosed a 0.8% decline in identical sales, $784M adjusted EBITDA and $0.36 EPS.

Expected impact

likely downside as investors price in weaker sales and limited guidance

Evidence & confidence

The disclosed decline in sales and lack of strong forward guidance suggest earnings disappointment, which typically triggers sell pressure.

Market effects

Retail grocery sector may face broader scrutiny as peers' earnings are compared to Albertsons' results.

U.S. consumer discretionary market could see slight weakness following the earnings miss.

Limited; primarily affects U.S. grocery and consumer stocks.

Counterpoint

If cost‑saving initiatives accelerate, the stock could rebound despite the near‑term earnings disappointment.

Key entities

  • Albertsons Companies

    U.S. grocery retailer reporting Q2 2026 earnings.

  • Meg Whitman

    New Executive Chair providing strategic commentary.

Related articles

$ACIMedAI 8/10

Albertsons Companies Q2 Earnings Call Highlights

Albertsons (ACI) reported Q2 earnings, highlighting a 1.5% decline in core business sales and a 26.8% gross margin. The company plans to accelerate cost savings, including centralized buying and potential headcount reductions, aiming for $2B in savings over three years. Albertsons generated $1.2B in operating cash flow and repurchased $175M in shares. Management is reviewing its portfolio and expects to provide an updated strategy and outlook by Q4.

$KRMedAI 8/10

Grocer demands more than $9B from Kroger after $25B deal collapsed

Albertsons sued Kroger in Delaware, seeking over $9B after their $24.6B merger collapsed. Albertsons claims Kroger failed to secure regulatory approval and breached the agreement. The suit includes a $600M termination fee, $75M in costs, and a premium for stockholders. Kroger allegedly refused to alter its divestment plan.

$ACIMed

Albertsons Stock (ACI) Slumps as Boss Announces Full Business Review and Annual Guidance Delay

Albertsons (ACI) shares fell after CEO Susan Morris announced a full business review and delayed annual guidance. Q2 earnings per share beat estimates at $0.36, but revenue declined slightly to $18.89B. Pharmacy and digital sales grew, while net income dropped to $51.5M. The company also seeks $9B from Kroger over a failed merger. Analysts have a Hold consensus with a $13 price target.

$ACIMedAI 8/10

Albertsons suspends fiscal 2026 guidance, launches business review Q2

Albertsons reported a 69% drop in Q2 net income to $51.5M, with sales down 0.1% to $18.89B. Adjusted EPS of $0.36 and revenue beat analyst estimates. The company suspended fiscal 2026 guidance and launched a business review to cut costs and improve strategy, targeting an investor day in spring 2027. Albertsons also declared a $0.17 quarterly dividend and repurchased 26M shares for $387.6M. The company is pursuing a $9.3B lawsuit against Kroger over a failed merger.